-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2023-504998-20-00
5
2020-09-18
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2024-511832-29-00
4
2020-08-05
High risk adenocarcinoma of the prostate after radical prostatectomy
(
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2023-509089-39-00
5
2020-07-01
Non-Muscle Invasive Bladder Cancer
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-512704-20-00
4
2020-06-22
Unresectable and/or metastatic soft-tissue sarcoma after failure of at
-
2023-509394-23-00
5
2020-06-12
Stage II melanoma arising from a primary cutaneous site after surgery
-
2023-505042-25-00
5
2020-05-05
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
-
2024-513947-94-00
4
2020-03-30
locally advanced (stage III) and not suitable for curative treatment,
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-501531-16-00
5
2020-01-24
esophageal carcinoma
-
2024-514197-50-00
9
2020-01-17
CD123 positive Acute Myeloid Leukemia
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma
-
2023-504821-38-00
4
2019-09-19
Classical Hodgkin lymphoma in children and young adults
-
2022-500584-12-00
4
2019-09-11
Waldenström’s Macroglobulinemia
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2024-515769-32-00
5
2019-07-02
HR+/HER2- early breast cancer
-
2023-509216-28-00
4
2019-05-27
Generalized Pustular Psoriasis
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer